新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » CRO/CMO » Charles River收购Galapagos CRO业务

Charles River收购Galapagos CRO业务

来源:生物谷 2014-03-15 16:36

2014年3月15日讯 /生物谷BIOON/ --Charles River生物技术公司最近宣布公司已经和制药公司Galapagos达成价值1亿7千9百万美元的协议收购Galapagos公司的合约研究部门(CRO),今后Galapagos公司将专注于药物开发过程。而Charles River生物技术公司也通过这笔收购案进一步增强了公司CRO业务的实力。Charles River公司透露公司希望在第二季度完成这笔交易。

而2014年Charles River生物技术公司通过兼并扩大公司规模使公司预计年营业额达到13亿美元。与合约研究机构巨头Quintiles公司和Covance公司不同,Charles River公司的合约研究业务并没有涵盖医药研发所有环节,而是集中精力于药物的早期研究过程。此次公司收购Galapagos公司的研发部门将进一步增强公司在早期研发领域的实力。(生物谷Bioon.com)

详细英文报道:

Charles River Laboratories ($CRL) is looking to pad its preclinical prowess, inking a $179 million deal with drugmaker Galapagos for two CRO subsidiaries and a chance to expand its in vitro biology expertise.

Under the deal, expected to close next quarter, Charles River will hand over $179 million up front and up to $7 million in performance payments in exchange for Argenta and BioFocus, contract researchers that brought in $87 million in sales last year. Charles River figures its new acquisitions will grow another 10% in 2014, adding about 6% to its projected annual sales of $1.3 billion.

Galapagos' two CROs specialize in medicinal chemistry, target discovery and complex in vitro biology, Charles River said, and the deal will add more than 340 scientists to its ranks of preclinical experts. While end-to-end giants like Quintiles ($Q) and Covance ($CVD) strive to cover every stage of development, Charles River has entrenched itself in the early-phase segment, and this acquisition will only deepen its dominance of the preclinical market, CEO James Foster said.

"Argenta and BioFocus' upstream in vitro capabilities will be an excellent fit with our in vivo expertise and will enable us to engage with our clients earlier in the drug discovery process," Foster said in a statement. "This enhances the value we can provide to our clients because it allows them to outsource integrated drug discovery and early-stage development programs to a single provider."

Meanwhile, for Galapagos, the move allows it to cash out of the CRO world and redouble investments in its pipeline, which includes collaborations with GlaxoSmithKline ($GSK), AbbVie ($ABBV) and Johnson & Johnson ($JNJ). The Belgian biotech endured a setback earlier this month when GSK pushed pause on a study of the Galapagos-partnered lupus drug GSK2586184, casting doubts on a treatment that had already run into trouble in ulcerative colitis.

Once the deal is wrapped, Galapagos Services CEO David Smith will stay at the helm of Argenta and BioFocus, joining Charles River as vice president of in vitro discovery services. The acquisition also gives Charles River outposts in the U.K. and the Netherlands.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库